Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials

[1]  A. Schneeweiss,et al.  Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? , 2016, Annals of Surgical Oncology.

[2]  H. Kuerer,et al.  Targeting and limiting surgery for patients with node-positive breast cancer , 2015, BMC Medicine.

[3]  J. White,et al.  Imaging of the axilla before preoperative chemotherapy: Implications for postmastectomy radiation , 2015, Cancer.

[4]  K. Hunt,et al.  Axillary Ultrasound After Neoadjuvant Chemotherapy and Its Impact on Sentinel Lymph Node Surgery: Results From the American College of Surgeons Oncology Group Z1071 Trial (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  E. Rutgers,et al.  Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. , 2015, Annals of surgery.

[6]  H. Kuerer,et al.  Selective surgical localization of axillary lymph nodes containing metastases in patients with breast cancer: a prospective feasibility trial. , 2015, JAMA surgery.

[7]  M. Brackstone,et al.  Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  B. Adrada,et al.  Histopathologic Correlation of Residual Mammographic Microcalcifications After Neoadjuvant Chemotherapy for Locally Advanced Breast Cancer , 2015, Annals of Surgical Oncology.

[9]  M. Su.  Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Research Consortium Trial 017 , 2013 .

[10]  D. Rea,et al.  Time to stop operating on breast cancer patients with pathological complete response? , 2013, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[11]  J. Boughey,et al.  Imaging Response and Residual Metastatic Axillary Lymph Node Disease after Neoadjuvant Chemotherapy for Primary Breast Cancer , 2013, Annals of Surgical Oncology.

[12]  T. Fehm,et al.  Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. , 2013, The Lancet. Oncology.

[13]  N. Hylton,et al.  Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer , 2013, Cancer.

[14]  Les Irwig,et al.  Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. , 2013, Journal of the National Cancer Institute.

[15]  S. Rodenhuis,et al.  Early Assessment of Axillary Response with 18F-FDG PET/CT during Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: Implications for Surgical Management of the Axilla , 2013, Annals of Surgical Oncology.

[16]  Petra Macaskill,et al.  Meta-analysis of the association of breast cancer subtype and pathologic complete response to neoadjuvant chemotherapy. , 2012, European journal of cancer.

[17]  Giulia Bianchi,et al.  Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[18]  Janet Waters,et al.  MRI for breast cancer screening, diagnosis, and treatment , 2011, The Lancet.

[19]  T. Julian,et al.  Accuracy of Clinical Examination, Digital Mammogram, Ultrasound, and MRI in Determining Postneoadjuvant Pathologic Tumor Response in Operable Breast Cancer Patients , 2011, Annals of Surgical Oncology.

[20]  M. Bollet,et al.  Is radiotherapy an option for early breast cancers with complete clinical response after neoadjuvant chemotherapy? , 2011, International journal of radiation oncology, biology, physics.

[21]  S. Rodenhuis,et al.  Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Campone,et al.  FDG PET evaluation of early axillary lymph node response to neoadjuvant chemotherapy in stage II and III breast cancer patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[23]  Gang Huang,et al.  Is 18F-FDG PET accurate to predict neoadjuvant therapy response in breast cancer? A meta-analysis , 2011, Breast Cancer Research and Treatment.

[24]  H. Kuerer,et al.  Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2‐positive breast cancer , 2010, Cancer.

[25]  William E Gillanders,et al.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. , 2010, American journal of surgery.

[26]  S. Raza,et al.  Can Breast MRI Predict Axillary Lymph Node Metastasis in Women Undergoing Neoadjuvant Chemotherapy , 2010, Annals of Surgical Oncology.

[27]  L. Turnbull.  Dynamic contrast‐enhanced MRI in the diagnosis and management of breast cancer , 2009, NMR in biomedicine.

[28]  Orhan Nalcioglu,et al.  MRI evaluation of pathologically complete response and residual tumors in breast cancer after neoadjuvant chemotherapy , 2008, Cancer.

[29]  K. Hess,et al.  Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  S. Vinnicombe,et al.  Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer , 2008, British Journal of Cancer.

[31]  D. Hsiang,et al.  Predicting nodal status using dynamic contrast-enhanced magnetic resonance imaging in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy with and without sequential trastuzumab. , 2007, Archives of surgery.

[32]  P. Sauven,et al.  The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[33]  S. Singletary,et al.  Accuracy of the Combination of Mammography and Sonography in Predicting Tumor Response in Breast Cancer Patients After Neoadjuvant Chemotherapy , 2006, Annals of Surgical Oncology.

[34]  S. Alvarez,et al.  Role of sonography in the diagnosis of axillary lymph node metastases in breast cancer: a systematic review. , 2006, AJR. American journal of roentgenology.

[35]  G. Hortobagyi,et al.  Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer , 1998, Annals of Surgical Oncology.

[36]  Mark A. Helvie,et al.  Clinical and Radiologic Assessments to Predict Breast Cancer Pathologic Complete Response to Neoadjuvant Chemotherapy , 2005, Breast Cancer Research and Treatment.

[37]  J. Ioannidis,et al.  Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. , 2005, Journal of the National Cancer Institute.

[38]  A. Meyer,et al.  High-resolution axillary ultrasound is a poor prognostic test for determining pathologic lymph node status in patients undergoing neoadjuvant chemotherapy for locally advanced breast cancer. , 2004, American journal of surgery.

[39]  Development of Malignant Breast Microcalcifications After Neoadjuvant Chemotherapy in Advanced Breast Cancer , 2004, The breast journal.

[40]  W. Allum,et al.  Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  H. Tsuda,et al.  Concordance in pathological response to neoadjuvant chemotherapy between invasive and noninvasive components of primary breast carcinomas , 2002, Breast cancer.

[42]  S. Singletary,et al.  The correlation of axillary ultrasonography with histologic breast cancer downstaging after induction chemotherapy. , 2000, American journal of surgery.

[43]  G. Hortobagyi,et al.  Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  G. MacGrogan,et al.  Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS). , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  P. Ellis,et al.  Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  E. Touboul,et al.  Possibility of conservative local treatment after combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer. , 1996, International journal of radiation oncology, biology, physics.

[47]  J E Husband,et al.  Primary breast cancer: mammographic changes after neoadjuvant chemotherapy, with pathologic correlation. , 1996, Radiology.

[48]  B. Asselain,et al.  Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. , 1995, European journal of cancer.

[49]  D. King,et al.  Mammography in the assessment of response to medical treatment of large primary breast cancer. , 1993, Clinical radiology.

[50]  A. Korzun,et al.  Combination chemotherapy with mastectomy or radiotherapy for stage III breast carcinoma: a Cancer and Leukemia Group B study. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  G. Bonadonna,et al.  Multimodal treatment for locally advanced breast cancer. Result of chemotherapy-radiotherapy versus chemotherapy-surgery. , 1981, Cancer clinical trials.

[52]  K. Abromeit.  Music Received , 2023, Notes.